GHRP-6 — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

GHRP-6

Also known as: Growth Hormone-Releasing Peptide-6, Growth Hormone-Releasing Hexapeptide-6, His-(D-Trp)-Ala-Trp-(D-Phe)-Lys-NH2, GH-Releasing Peptide 6

Synthetic peptide GH secretagogue (growth hormone-releasing peptide); GHS-R1a agonist

Research chemicalLast updated: October 31, 2026Based on 45 peer-reviewed studies

What it is

GHRP-6 is a peptide people use to boost growth hormone output for muscle recovery, body composition, and general wellness. It's also used in clinical research as a diagnostic test for GH deficiency. Not FDA-approved for therapeutic use; banned by WADA; studied in organ protection and metabolic research.

The scientific side

GHRP-6 (His-(D-Trp)-Ala-Trp-(D-Phe)-Lys-NH2; MW 872.44 Da) is a synthetic hexapeptide that stimulates GH secretion by binding to the GH secretagogue receptor (GHS-R), acting through mechanisms distinct from those of GHRH (PMID 36869809; PMID 8421084; PMID 7920995). Its intracellular signalling involves protein kinase C (PKC) activation, phosphatidylinositol (PI) turnover, and mobilisation of intracellular Ca2+ (PMID 7772238; PMID 8175966). In GH3 cells, GHRP-6 induces CREB phosphorylation and GH secretion via a PKCσ-dependent pathway. GHRP-6 also upregulates Pit-1 transcription via PKC, MAPK kinase, and PKA activation. Evidence from patients with hypothalamo-pituitary disconnection indicates that its primary action is exerted at the hypothalamic level, requiring an intact hypothalamo-pituitary axis for full GH-releasing activity, though a direct pituitary action also exists (PMID 7883854; PMID 7593423). GHRP-6 also stimulates ACTH and cortisol release and has demonstrated cytoprotective, anti-inflammatory, and tissue-regenerative effects in animal models independent of GH secretion (PMID 16417467; PMID 41534456; PMID 41327290; PMID 41901314). GHRP-6 was found to bind to melanocortin MC1 and MC5 receptors in vitro, though at low affinity.

Class: Synthetic peptide GH secretagogue (growth hormone-releasing peptide); GHS-R1a agonist

Administration & storage

Administration
Intravenous bolus (PMID: 23099431PMID: 8421084PMID: 7883854PMID: 12809173PMID: 15817913)Intravenous infusion (PMID: 17112585)Intraperitoneal (animal studies: PMID: 16417467PMID: 26311576PMID: 30390209)Subcutaneous (animal study: PMID: 21704671)Oral/per os (human studies: PMID: 7581965PMID: 8051337; animal study: PMID: 8374685)Intranasal (human metabolite study: PMID: 25869809)Oral aquafeed (fish study: PMID: 40906090)
Storage
No storage conditions for GHRP-6 preparations are described in the reviewed abstracts. The LC-MS bioanalytical validation study confirmed analyte and internal standard stability under conditions experienced during real-time analysis (specific conditions not detailed in abstract).
Cautions
In the only identified human Phase I pharmacokinetic study (9 healthy male volunteers), atypical GHRP-6 concentration spikes were observed during the elimination phase in 4 of 9 subjects at all dose levels tested; clinical significance is unknown.,During GHRP-6 IV administration in a diagnostic study, flush symptoms were the only side effects reported; no serious adverse events were described in that study.,GHRP-6 stimulates ACTH and cortisol release in addition to GH; exaggerated ACTH/cortisol responses have been documented in Cushing's disease and Addison's disease patients, indicating caution in individuals with HPA axis disorders (PMID: 12809173; PMID: 12739742; PMID: 16832586).,GHRP-6 is listed on the WADA Prohibited List; use by competitive athletes carries doping sanction risk.,Available human safety data are limited to short-duration, single-dose IV administrations in clinical research settings. Long-term safety, chronic dosing effects, and safety of self-administered or non-IV routes in non-research settings have not been reported in the reviewed literature.,Sterile technique is essential for any injectable preparation to prevent contamination and infection.

Legal & regulatory status

US FDA

Not stated in reviewed literature — requires manual verification

WADA

Listed on the World Anti-Doping Agency (WADA) Prohibited List

Health Canada

Not stated in reviewed literature — requires manual verification